Sustainability | January 07, 2026
WuXi Biologics secures ISO 20400 certification
WuXi Biologics has integrated sustainability principles throughout its supplier lifecycle management
WuXi Biologics has integrated sustainability principles throughout its supplier lifecycle management
The company previously completed a $150 million venture investment, acquisition, and recapitalization
Coverage has been significantly strengthened across key therapeutic categories, including anti-tubercular, anti-diabetic and anti-cancer medicines, as well as iron supplements, thereby ensuring more comprehensive standardisation of medicines used under various National Health Programmes
Leaders from science, policy, industry, and investment came together in New Delhi to examine how alignment across the biotechnology value chain can turn innovation into outcomes at scale
The company views ESG reporting as a strategic tool to build trust with clients, investors, regulators, and stakeholders worldwide
This development marks a substantial improvement in the company's financial position and reflects strengthened promoter confidence
Healthcare and insurance are not parallel systems; they are interdependent pillars of patient trust
The initiative is focused on a problem that continues to plague cancer outcomes in India
The pharma company will donate more than seven tons of its active pharmaceutical ingredient (API) to bolster the American supply chain
The company had achieved the highest "A" rating in Climate Change
Subscribe To Our Newsletter & Stay Updated
